Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06435468

Biocollection of Rare Pediatric-onset of Autoimmune and Autoinflammatory Diseases

Rare diseases are defined as those that affect one person in 2,000, or around three million people in France. The majority of rare diseases are caused by genetics and tend to be severe when they begin in childhood. Autoimmune and autoinflammatory diseases, such as systemic lupus, juvenile dermatomyositis, and juvenile idiopathic arthritis, are examples of rare pediatric diseases. While autoimmune diseases are characterized by an inappropriate adaptive immune response, autoinflammatory diseases involve an excess of the innate immune response. The precise mechanisms of these diseases are not yet fully understood, but recent research has led to advances in their diagnosis and identification, particularly in early onset and familial forms. However, the rarity of these diseases and limited availability of biological samples pose significant challenges.

This study aims to create a biological collection, which includes primary cells (PBMC), DNA, RNA, lymphoblastic lines, and serum, that will help identify genetic and immunological abnormalities in rare autoimmune and autoinflammatory diseases through various research projects.

Recruiting

Interested in participating?

Request Info

Key information

Age range

1 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Service de rhumatologie pédiatrique Hôpital Femme-Mère-enfant, Bron, France

Loading trial locations.

About this study

A disease is said to be "rare" when it affects one person in 2,000, which represents three million people in France. Most rare diseases (80%) are genetic in origin ; the earlier they start in childhood, the more severe they can be. Rare pediatric diseases include autoimmune diseases (systemic lupus, juvenile dermatomyositis and juvenile idiopathic arthritis) and autoimmune diseases (interferonopathies, FMF, CAPS, TRAPS, and DADA2). Systemic autoimmune diseases are characterized by an inappropriate adaptive immune response (mediated by autoreactive T and/or B lymphocytes) with the production of autoantibodies directed against the constituents of the self (tolerance breakdown). Autoinflammatory diseases, unlike autoimmune diseases, correspond to an excess in the innate immune response (cytokines, macrophages, NK cells, granulocytes, etc.)..The precise pathophysiological mechanisms of these diseases have yet to be fully elucidated. Recent research has led to advances in the diagnosis and identification of monogenic forms of these diseases, particularly in early onset, familial, and syndromic forms. Nevertheless, the rarity of these diseases and limited availability of biological samples are major challenges that need to be overcome.

Thus, the aims of this study were as follows:

  • The creation of a biological collection: primary cells (PBMC), DNA, RNA, lymphoblastic lines, and serum, which, through various research projects, will help identify genetic and immunological abnormalities in rare autoimmune and autoinflammatory diseases.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients
  • minor or adult patient of any age with a rare dysimmune disease characterized by autoimmunity or auto-inflammation or early lymphoproliferation, having started in childhood (<18 years), or syndromic or familial
  • relative of a minor or adult patient with a rare dysimmune disease characterized by autoimmunity or auto-inflammation or early lymphoproliferation, having started in childhood (<18 years of age) or syndromic or familial,
  • weight greater than 5 kg
  • Patient/parents/guardians who were informed of the study and signed the consent form.
  • patient affiliated to a social security scheme

Healthy volunteer participants

  • minor or adult participants with no age restrictions
  • weight over 5 kg
  • Subject /Parents/guardians who were informed of the study and signed a consent form.
  • Patient affiliated to a social security scheme

Exclusion criteria

Patients

  • Subjects /Parents/guardians, refusing to participate in the study

Healthy volunteer participants :

  • active infection (viral, bacterial, parasitic)
  • history of neoplasia (< 5 years) or current neoplasia
  • participants with a personal or family history of autoimmune disease
  • immunocompromised participant (immune deficiency or transplant recipient)
  • Subjects/parents/guardians refusing to participate in the study
  • Adults under legal protection (guardianship, curatorship)

Treatment and study plan

Blood sample for genetic analysis

Genetic

genetic analysis (WES, WGS) for the identification of germline and somatic mutations responsible for rare autoimmune diseases or auto-inflammatory pathologies (pediatric or syndromic or familial) that began in childhood

Blood sample for immunological response assessments

Other

Identifying specific immunological factors in patients with rare pediatric autoimmune and auto inflammatory diseases

Blood sample to identify relevant biomarker of the disease

Other

Research biomarkers for diagnosis, prognosis and monitoring of disease activity

Primary outcomes

  1. To Identify germline and somatic mutations responsible for rare autoimmune diseases or auto-inflammatory pathologies (pediatric or syndromic or familial) that began in childhood

    Time frame: Baseline

    Identification of germline or somatic genetic mutations, based on high-throughput sequencing data (exome, genome or transcriptome).

Secondary outcomes

  1. Measurement of disease activity according to Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)

    Time frame: Baseline

    score (Min value: 0 - Max value: 105), with higher values mean higher disease activity

  2. Levels of anti-double stranded DNA

    Time frame: Baseline

    in patients sera

  3. Levels of complement components C3 and C4

    Time frame: Baseline

    in patients sera

  4. Level of IFN Signature score

    Time frame: Baseline

    Mesured by 6-gene Type 1 IFN Signature Score

  5. Concentration of circulating IFN-alpha

    Time frame: Baseline

    In serum using single-molecule array digital ELISA technology (Simoa)

  6. Presence or absence of anti-type I interferons autoantibodies

    Time frame: Baseline

    in patients sera

Study contacts

Contact information is provided by the study sponsor or research team.

BELOT Alexandre, Pr

CONTACT

[email protected]

+ 33 4 27 85 61 26

PLASSART Samira

CONTACT

[email protected]

+ 33 4 27 85 54 42

Sponsors and collaborators

Lead sponsor

Hospices Civils de Lyon

Other

Registry information

Official study title

Biocollection for the Study of Genetic and Immunological Abnormalities in Rare Pediatric-onset Autoimmune and Auto Inflammatory Diseases

Acronym: GENIALII

Important dates

Study start
2025
Primary completion
2035
Study completion
2035
First posted
May 30, 2024
Registry last updated
Dec 22, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.